Clinical Trials
4 trialsNCT05319873 2026-05-11
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT05230810 2026-03-16
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Criterium, Inc.
Phase 1/2 Active not recruiting
NCT01992952 2025-11-26
FAKTION
Velindre NHS Trust
Phase 1/2 Active not recruiting
NCT05251714 2025-05-18
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
Treadwell Therapeutics, Inc
Phase 1/2 Active not recruiting